ISTH 0036

Drug Profile

ISTH 0036

Alternative Names: ISTH0036

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator Isarna Therapeutics
  • Class Antiglaucomas; Antisense oligonucleotides
  • Mechanism of Action Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scars
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma

Most Recent Events

  • 04 May 2016 Interim adverse events data from a phase I trial in Glaucoma released by Isarna Therapeutics
  • 21 May 2015 ISTH 0036 receives Orphan Drug status for Scars prevention in European Union
  • 11 May 2015 Pharmacodynamics data from a preclinical trial in Glaucoma released by Isarna Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top